Scholarlink

Introduction <p>Understanding of real-world clinical practice for patients with atopic dermatitis (AD) in the Middle East is limited. We aimed to describe clinical characteristics, treatment patterns and disease burden for adult patients.</p> Methods <p>Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of qualified dermatologists and their patients in the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar and Turkey between September 2022 and March 2023. Dermatologists reported patient demographics, clinical characteristics and treatment history. Patients reported the Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), EQ-5D-5L, and Work Productivity and Activity Impairment questionnaire.</p> Results <p>Overall, 209 dermatologists reported data on 736 patients, of whom 437 self-reported data. Dermatologists subjectively determined that 200 patients had ‘mild’, 283&#xa0;had ‘moderate’ and 253&#xa0;had ‘severe’ AD at survey. Mean (SD) patient age was 28.8 (8.1)&#xa0;years; 50% were male and 50% female. Overall mean (SD) POEM scores were 9.7 (5.5), DLQI were 9.7 (5.5), EQ-5D-5L were 0.72 (0.29) and overall work impairment was 46.0% (22.3%). Majority were prescribed topical treatments (89%), 18% received systemic immunosuppressants and 13% received biologics.</p> Conclusions <p>Our findings highlight the disease burden and need to use more efficacious treatment in the Middle East, to improve clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Patterns and Burden of Atopic Dermatitis in Adults in the United Arabic Emirates, Saudi Arabia, Kuwait, Qatar and Turkey: A Real-World Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Peter Anderson,
  • Jenny Austin,
  • Mohamed Elrayes,
  • Soniya Rai,
  • Soydan Ince,
  • Mufaddal Alaithan,
  • Fatimah Al-Breiki,
  • Martin Steinhoff,
  • Mohammed Fatani,
  • Emel Bülbül Başkan,
  • Atlal Al-Lafi,
  • James Piercy

摘要

Introduction

Understanding of real-world clinical practice for patients with atopic dermatitis (AD) in the Middle East is limited. We aimed to describe clinical characteristics, treatment patterns and disease burden for adult patients.

Methods

Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of qualified dermatologists and their patients in the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar and Turkey between September 2022 and March 2023. Dermatologists reported patient demographics, clinical characteristics and treatment history. Patients reported the Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), EQ-5D-5L, and Work Productivity and Activity Impairment questionnaire.

Results

Overall, 209 dermatologists reported data on 736 patients, of whom 437 self-reported data. Dermatologists subjectively determined that 200 patients had ‘mild’, 283 had ‘moderate’ and 253 had ‘severe’ AD at survey. Mean (SD) patient age was 28.8 (8.1) years; 50% were male and 50% female. Overall mean (SD) POEM scores were 9.7 (5.5), DLQI were 9.7 (5.5), EQ-5D-5L were 0.72 (0.29) and overall work impairment was 46.0% (22.3%). Majority were prescribed topical treatments (89%), 18% received systemic immunosuppressants and 13% received biologics.

Conclusions

Our findings highlight the disease burden and need to use more efficacious treatment in the Middle East, to improve clinical outcomes.